A campus-wide Prostate Cancer Research Program has been developed with collaboration of multiple schools and institutes at UCLA. The Prostate Cancer Program area has recently been named a full Program Area of the Jonsson Comprehensive Cancer Center (JCCC). This germinal program provides the basis for this SPORE application. The purpose of the SPORE is, along with other SPORE institutions, to contribute to the progress in the diagnosis, prevention, and treatment of prostate cancer. The SPORE project has two major objectives: 1. To develop multiple translational basic research and community-based research projects with an emphasis on minority populations. Four laboratory research projects will apply institutional research on gene expression and signaling, to prognosis and treatment of prostate cancer. One project will build on the experience of institutional investigators to address innovative aspects of dietary control of prostate cancer. 2. To develop new prostate cancer research and career development to advance translational research. This will be effected through existing and continued institutional support as well as career development programs and developmental research programs. The emphasis in all research projects is rapid translation to clinical trials. Existing clinical research programs have been coordinated to provide the best possible access to study patients with all stages of prostate cancer. The four basic research projects are linked, in that they a) are clearly translatable, b) are based on basic work within the individual investigator's own laboratories, and c) provide new strategies for targeting specific signaling pathways important in prostate cancer. Information from these studies also provides prognostic information and will add to the current clinical and molecular markers of prognosis for localized prostate cancer. An external Advisory Board will participate in the supervision and analysis of SPORE progress in all research and administrative areas. In collaboration with the JCCC, the SPORE represents a major interdisciplinary, collaborative, and translational program which promises to make a significant impact on prostate cancer mortality and morbidity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA092131-01A1
Application #
6462877
Study Section
Special Emphasis Panel (ZCA1-GRB-V (J1))
Program Officer
Hruszkewycz, Andrew M
Project Start
2002-09-15
Project End
2007-06-30
Budget Start
2002-09-15
Budget End
2003-06-30
Support Year
1
Fiscal Year
2002
Total Cost
$1,888,201
Indirect Cost
Name
University of California Los Angeles
Department
Urology
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Cheng, Larry C; Li, Zhen; Graeber, Thomas G et al. (2018) Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer. J Vis Exp :
Park, Jung Wook; Lee, John K; Sheu, Katherine M et al. (2018) Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362:91-95
Tan, Nelly; Shen, Luyao; Khoshnoodi, Pooria et al. (2018) Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. J Urol 199:1218-1223
Donin, Nicholas M; Reiter, Robert E (2018) Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med 59:177-182
Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496
Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82
Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482

Showing the most recent 10 out of 339 publications